July 25, 2025—MeMed has completed its multiyear development of MeMed BV Flex, a next-generation test designed to expand the reach of MeMed BV into decentralized, CLIA-waived settings. The test enables differentiation between bacterial and viral infections in 15 minutes using capillary blood from a finger prick.
“Accurately and simultaneously measuring multiple proteins from just a few drops of blood, in a rapid and easy-to-use format, has been a long-standing challenge,” Eran Eden, PhD, cofounder and CEO of MeMed, said in a press release. “By pairing this breakthrough with machine learning, we’ve enhanced our platform, which, once cleared, can help extend host-response testing across broader decentralized use.”
The test was verified in a prospective analytical study, demonstrating performance comparable to advanced laboratory methods. A multicenter pivotal study is underway to confirm clinical accuracy and support regulatory submission. The test has not been approved for sale by any regulatory authority.